Innovative Biologics Will Drive Sales of Cancer Drugs Over Next Four Years

Share Article

Genentech and Roche likely to enjoy best growth, says URCH report.

Future growth in sales of pharmaceutical treatments for cancer will primarily come from the emergence of innovative biologics and the monoclonal antibody class of drugs, says a new report from specialist information provider, URCH Publishing.

The leading monoclonal antibodies, Rituxan® and MabThera (rituximab), Herceptin® (trastuzumab) and Avastin® (bevacizumab) all experienced annual growth rates in excess of 20 percent in 2005. Furthermore, these three drugs are currently undergoing significant lifecycle development amounting a total of more than 15 late stage clinical trials in 2006 (phase II or later), says "Cancer Market Trends 2006-2010: Key market forecasts and growth opportunities," published today.

Despite only being launched in 2004, Avastin's lifecycle management program is forecast to generate sales of over $9 billion by 2010, overtaking Rituxan/ MabThera as the leading cancer drug by global sales revenue.

As a consequence of the strong growth forecast for the leading cancer monoclonal antibodies, Genentech and Roche will enjoy the greatest amount of growth among the leading cancer market players through to 2010. "Genentech is forecast to grow its cancer sales from fifth highest among cancer manufacturers in 2005 to second place in 2010 behind Amgen. Over the same period, Roche will be 'promoted' above current second placed Novartis," says Steve Seget, author of the report.

With Amgen, Genentech and Roche predicted to be marketing the five leading cancer drugs in 2010, as well as comprising the lead positions amongst cancer manufacturers, the cancer market will enter a new age over the next five years, dominated by biotechnology-derived products marketed by biotechnology-focused companies.

The global cancer market grew to $50.3 billion in 2005, a year-on-year increase of 16.5 percent. Between 2003 and 2005, global cancer sales increased by 40 percent and accounted for 8.4 percent of total global pharmaceutical sales in 2005, notes the 111-page report.

"Cancer Market Trends 2006-2010: Key market forecasts and growth opportunities" is a comprehensive report with market forecasts and overviews for pharmaceutical business decision-making. The publication contains 49 figures and 43 tables and will be of particular use to those involved in corporate planning, sales and marketing, portfolio management and market forecasting.

Report content in brief:

Chapter 1 Introduction

Chapter 2 Key disease markets Key cancer markets

Chapter 3 Key drug classes Key drug classifications

Chapter 4 Key products

Chapter 5 Key companies

Chapter 6 Key trends and opportunities

Key product forecasts

-Aranesp (darbepoetin alfa)

-Eloxatin (oxaliplatin)

-Epogen (epoetin alfa)

-Eprex/ Procrit (epoetin alfa)

-Gleevec/ Glivec (imatinib mesylate)

-Lupron (leuprolide acetate)

-NeoRecormon/ Epogin (epoetin beta)

-Neulasta (pegfilgrastim)

-Rituxan/ MabThera (rituximab)

-Taxotere (docetaxel)

Key company forecasts

-Amgen

-AstraZeneca

-Eli Lilly

-Genentech

-GlaxoSmithKline

-Johnson & Johnson

-Novartis

-Pfizer

-Roche

-Sanofi-Aventis

"Cancer Market Trends 2006-2010: Key market forecasts and growth opportunities" is available from URCH Publishing. Find more details at

http://www.urchpublishing.com/publications/therapeutic/cancer_market_trends_2006.html

About URCH Publishing Ltd (http://www.urchpublishing.com)

URCH Publishing Ltd is an independent business information publisher dedicated to delivering quality information products to the global pharmaceuticals industry. For more information contact URCH Publishing on +44 (0) 20 7060 1099 or email.

Press review copies may be available on request.

URCH Publishing, PO Box 27554, London SE4 2GZ, United Kingdom

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

JAMES ALEXANDER
Visit website